Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $754 from $755 and keeps an Overweight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron’s Gene Therapy Study: A Long-Term Look at Safety and Efficacy
- Regeneron’s Cemiplimab Study: A New Hope for Early-Stage Skin Cancer?
- Positive Outlook for Regeneron: Buy Rating Backed by FDA Approvals, Patent Extensions, and Growth Projections
- Regeneron Advances Immunotherapy Combinations for NSCLC: A Study Update
- QQQ ETF News, 7/8/2025